Delivery formulations

Bringing innovation & performance through new delivery forms. Introducing StabiCaps™ and SiMoGel™

Recorded the 11-Dec-2019 | Webinar

Rousselot will take you through challenges and opportunities in creating the perfect delivery form

Register for free

Controlled Nucleation: more than just a homogenization tool

Telstar Life Science Solutions | 30-Sep-2019 | Case Study

A new vacuum induced nucleation method in the freeze-drying process, Telstar Lyonuc, reduces the duration of the primary drying cycle and ensures the homogenization...

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Customized Fill Release in Gelatine Soft Capsules

Gelita AG | 07-May-2018 | Application Note

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Choosing the right excipient to meet future capsule challenges

Rousselot | Recorded the 31-Oct-2017 | Webinar

The primary goal of the pharmaceutical industry is to satisfy the therapeutic needs of patients.

Active ingredients are, of course, essential...

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

GELITA® Gelatine for State-of-the-Art Delivery Systems

Gelita AG | 21-Aug-2017 | Technical / White Paper

The latest development of the GELITA Competence Team is GELITA® RXL R2 that takes the reduced cross-linking (RXL) concept provided by GELITA® RXL one step...

First-in-Human Development Strategies

Catalent Pharma Solutions | 01-May-2017 | Insight Guide

Crucial and cost-effective factors to consider when transforming a pre-clinical development compound into a first-in-human, early-phase drug candidate....

BEPO, the enabling technology to long-acting injectable adoption

MEDINCELL | Recorded the 20-Apr-2017 | Webinar

Already in clinical stage, BEPO is MedinCell proprietary long-acting injectable (LAI) platform based on a combination of copolymers, solvent and active...